Evaluation of Extended Ustekinumab Dosing Intervals for Remission Maintenance in Refractory Ulcerative Colitis

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2026
This article has no abstract
Epistemonikos ID: e96dc4012872559b2af0128094d5f48106e131cb
First added on: Oct 10, 2026